Rogers Corp. Dl 1 Stock
Rogers Corp. Dl 1 Stock
Rogers Corp. Dl 1 gained 0.950% compared to yesterday.
So far the community has only identified positive things for Rogers Corp. Dl 1 stock. The most positive votes were given for criterium "Non-cyclic/Cyclic".
Pros and Cons of Rogers Corp. Dl 1 in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rogers Corp. Dl 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rogers Corp. Dl 1 | 0.950% | -7.018% | -25.874% | 85.965% | 34.177% | -30.263% | -32.484% |
| Vishay Intertechnology Inc. | 2.900% | -11.723% | -36.953% | 106.616% | 134.268% | 15.898% | 59.516% |
| Universal Display Corp. | -3.760% | -0.344% | -8.338% | -45.162% | -31.749% | -47.681% | -64.829% |
| Silicon Labs Inc. | 0.000% | -2.618% | -1.587% | 63.158% | 67.568% | 38.806% | 55.000% |
News
iRadimed Q2 Earnings Call Highlights
Key Points
- Interested in iRadimed Corporation? Here are five stocks we like better.
- iRadimed’s new 3870 pump is seeing strong demand: Second-quarter bookings exceeded shipments by more than
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Key Points
- Interested in Avalyn Pharma Inc.? Here are five stocks we like better.
- Avalyn Pharma is pursuing inhaled versions of approved pulmonary fibrosis drugs to reduce side effects that
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
Roger E. Susi, CEO, President, and Chairman of IRADIMED CORPORATION (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026
